Akebia Therapeutics, Inc. (AKBA)
AKBA Stock Price Chart
Explore Akebia Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze AKBA price movements and trends.
AKBA Company Profile
Discover essential business fundamentals and corporate details for Akebia Therapeutics, Inc. (AKBA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Mar 2014
Employees
181.00
Website
https://www.akebia.comCEO
John P. Butler MBA
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AKBA Financial Timeline
Browse a chronological timeline of Akebia Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.02, while revenue estimate is $52.06M.
Earnings released on 7 Aug 2025
EPS came in at $0.00 surpassing the estimated -$0.02 by +104.55%, while revenue for the quarter reached $62.47M , beating expectations by +30.45%.
Earnings released on 8 May 2025
EPS came in at $0.03 surpassing the estimated -$0.03 by +200.00%, while revenue for the quarter reached $57.34M , beating expectations by +12.87%.
Earnings released on 13 Mar 2025
EPS came in at -$0.10 falling short of the estimated -$0.05 by -100.00%, while revenue for the quarter reached $46.50M , beating expectations by +24.28%.
Earnings released on 7 Nov 2024
EPS came in at -$0.10 falling short of the estimated -$0.05 by -100.00%, while revenue for the quarter reached $37.43M , missing expectations by -8.51%.
Earnings released on 8 Aug 2024
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $43.65M , missing expectations by -11.73%.
Earnings released on 9 May 2024
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $32.61M , missing expectations by -34.06%.
Earnings released on 14 Mar 2024
EPS came in at $0.00 surpassing the estimated $0.00 by +100.00%, while revenue for the quarter reached $56.20M , beating expectations by +1.46%.
Earnings released on 8 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%, while revenue for the quarter reached $42.05M , missing expectations by -24.30%.
Earnings released on 25 Aug 2023
EPS came in at -$0.06 falling short of the estimated -$0.03 by -140.00%, while revenue for the quarter reached $56.38M , missing expectations by -4.61%.
Earnings released on 8 May 2023
EPS came in at -$0.14 surpassing the estimated -$0.15 by +6.67%, while revenue for the quarter reached $40.13M , missing expectations by -14.04%.
Earnings released on 9 Mar 2023
EPS came in at -$0.04 surpassing the estimated -$0.14 by +71.43%, while revenue for the quarter reached $55.18M , beating expectations by +16.41%.
Earnings released on 3 Nov 2022
EPS came in at -$0.28 falling short of the estimated -$0.15 by -86.67%, while revenue for the quarter reached $48.96M , beating expectations by +0.17%.
Earnings released on 4 Aug 2022
EPS came in at $0.23 surpassing the estimated -$0.31 by +174.19%, while revenue for the quarter reached $126.76M , beating expectations by +139.03%.
Earnings released on 9 May 2022
EPS came in at -$0.35 falling short of the estimated -$0.27 by -29.63%, while revenue for the quarter reached $61.70M , beating expectations by +39.37%.
Earnings released on 1 Mar 2022
EPS came in at -$0.40 falling short of the estimated -$0.33 by -21.21%, while revenue for the quarter reached $59.61M , beating expectations by +15.13%.
Earnings released on 4 Nov 2021
EPS came in at -$0.34 falling short of the estimated -$0.32 by -6.25%, while revenue for the quarter reached $48.76M , beating expectations by +3.06%.
Earnings released on 5 Aug 2021
EPS came in at -$0.51 falling short of the estimated -$0.30 by -70.00%, while revenue for the quarter reached $52.91M , beating expectations by +34.68%.
Earnings released on 10 May 2021
EPS came in at -$0.45 falling short of the estimated -$0.33 by -36.36%, while revenue for the quarter reached $52.30M , beating expectations by +22.09%.
Earnings released on 25 Feb 2021
EPS came in at -$0.60 falling short of the estimated -$0.43 by -39.53%, while revenue for the quarter reached $56.70M , beating expectations by +10.83%.
Earnings released on 5 Nov 2020
EPS came in at -$0.42 falling short of the estimated -$0.23 by -82.61%, while revenue for the quarter reached $59.99M , beating expectations by +147.06%.
AKBA Stock Performance
Access detailed AKBA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.